Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 152Lymphoma, Mantle-Cell 30Lymphoma, Non-Hodgkin 22Lymphoma, Follicular 22Lymphoma 22Recurrence 21Neoplasms, Plasma Cell 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 11Lymphoma, Large B-Cell, Diffuse 11Immunoglobulin Light-chain Amyloidosis 10Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, B-Cell 7Leukemia 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Amyloidosis 5Lymphoma, Large-Cell, Immunoblastic 4Hematologic Diseases 4Congenital Abnormalities 4Prostatic Neoplasms 3Paraproteinemias 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

liposomal doxorubicin 1Widowhood 1Videotape Recording 1Surveys and Questionnaires 1Melphalan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Patient Participation × Bortezomib × Clear all
NCT00985907 2020-06-17

DMV

University of California, San Francisco

Phase 1/2 Terminated
13 enrolled 8 charts
Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡